Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Immunopharmacology|March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammationLi Fu, Dean Gilham, Stephanie C Stotz, et al.
Kidney International Reports|June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal DiseaseSylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines|June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal ImpairmentDean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
Pharmacology Research & Perspectives|April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapyLi Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
JAMA|March 29, 2020
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical TrialKausik K Ray, Stephen J Nicholls, Kevin A Buhr, et al.
American Heart Journal|September 15, 2019
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trialKausik K Ray, Stephen J Nicholls, Henry D Ginsberg, et al.
Cardiovascular Diabetology|January 8, 2021
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE studyStephen J Nicholls, Gregory G Schwartz, Kevin A Buhr, et al.
Atherosclerosis|November 27, 2018
Apabetalone downregulates factors and pathways associated with vascular calcificationDean Gilham, Laura M Tsujikawa, Christopher D Sarsons, et al.
Cardiovascular Diabetology|June 23, 2021
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trialGregory G Schwartz, Stephen J Nicholls, Peter P Toth, et al.
Cardiovascular Therapeutics|August 22, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular DiseaseSylwia Wasiak, Dean Gilham, Emily Daze, et al.
Pageof 4